Amgen Inc. (AMGN)
4 Healthcare Stocks Poised to Crush Q4 Earnings Estimates
Rising patient volumes, technological advancements, rate hikes and other factors are likely to have benefited healthcare players during Q4. Companies like AMGN, COR, HUM and ARDT are likely to outperform.
Here's Why Amgen (AMGN) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amgen Set to Report Q4 Earnings: Is a Beat in the Cards?
Volume growth of AMGN's key drugs like Prolia, Repatha and Evenity is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Here's Why Amgen (AMGN) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amgen (AMGN) Stock Dips While Market Gains: Key Facts
The latest trading day saw Amgen (AMGN) settling at $280.30, representing a -0.94% change from its previous close.
Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth
Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Most-Watched Stock Amgen Inc. (AMGN) Worth Betting on Now?
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Amgen (AMGN) Surpasses Market Returns: Some Facts Worth Knowing
Amgen (AMGN) reachead $277.88 at the closing of the latest trading day, reflecting a +1.62% change compared to its last close.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Amgen's Lumakras Gets FDA Nod for Expanded Use in Colorectal Cancer
The FDA approves Amgen's Lumakras in combination with Vectibix for treating previously treated adults with KRAS G12C-mutated metastatic colorectal cancer.
Amgen (AMGN) Rises Yet Lags Behind Market: Some Facts Worth Knowing
In the latest trading session, Amgen (AMGN) closed at $272.11, marking a +0.99% move from the previous day.
US FDA approves Amgen's colorectal cancer therapy
The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients with a specific gene mutation.
